Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy.

ABSTRACT:

Background

Immune checkpoint blockades (ICBs) have emerged as a promising treatment for cancer. Recently, tumour mutational burden (TMB) and neoantigen load (NAL) have been proposed to be potential biomarkers to predict the efficacy of ICB; however, they were limited by difficulties in defining the cut-off values and inconsistent detection platforms. Therefore, it is critical to identify more effective predictive biomarkers for screening patients who will potentially benefit from immunotherapy. In this study, we aimed to identify comutated signaling pathways to predict the clinical outcomes of immunotherapy.

Methods

Here, we comprehensively analysed the signaling pathway mutation status of 9763 samples across 33 different cancer types from The Cancer Genome Atlas (TCGA) by m

SUBMITTER: Qiu J 

PROVIDER: S-EPMC9783967 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature